AU2020382911A1 - Treatment and prevention of Dengue disease - Google Patents

Treatment and prevention of Dengue disease Download PDF

Info

Publication number
AU2020382911A1
AU2020382911A1 AU2020382911A AU2020382911A AU2020382911A1 AU 2020382911 A1 AU2020382911 A1 AU 2020382911A1 AU 2020382911 A AU2020382911 A AU 2020382911A AU 2020382911 A AU2020382911 A AU 2020382911A AU 2020382911 A1 AU2020382911 A1 AU 2020382911A1
Authority
AU
Australia
Prior art keywords
compound
dengue
logio copies
logio
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020382911A
Other languages
English (en)
Inventor
Jean-François BONFANTI
Olivia Gabriella M. Goethals
Tim Hugo Maria Jonckers
Suzanne Kaptein
Bart Rudolf Romanie Kesteleyn
Johan Neyts
Bart Henri Theresia Stoops
Marnix Van Loock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Katholieke Universiteit Leuven
Janssen Pharmaceuticals Inc
Original Assignee
Katholieke Universiteit Leuven
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katholieke Universiteit Leuven, Janssen Pharmaceuticals Inc filed Critical Katholieke Universiteit Leuven
Publication of AU2020382911A1 publication Critical patent/AU2020382911A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2020382911A 2019-11-15 2020-11-13 Treatment and prevention of Dengue disease Pending AU2020382911A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP19209593 2019-11-15
EP19209593.3 2019-11-15
EP19213851.9 2019-12-05
EP19213851 2019-12-05
EP20171172 2020-04-23
EP20171172.8 2020-04-23
PCT/EP2020/082102 WO2021094563A1 (en) 2019-11-15 2020-11-13 Treatment and prevention of dengue disease

Publications (1)

Publication Number Publication Date
AU2020382911A1 true AU2020382911A1 (en) 2022-06-30

Family

ID=73288639

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020382911A Pending AU2020382911A1 (en) 2019-11-15 2020-11-13 Treatment and prevention of Dengue disease

Country Status (14)

Country Link
US (1) US20220409583A1 (https=)
EP (1) EP4058019A1 (https=)
JP (1) JP2023502053A (https=)
KR (1) KR20220101679A (https=)
CN (1) CN114980884A (https=)
AU (1) AU2020382911A1 (https=)
BR (1) BR112022009199A2 (https=)
CA (1) CA3161338A1 (https=)
IL (1) IL292970A (https=)
MX (1) MX2022005879A (https=)
PH (1) PH12022551160A1 (https=)
TW (1) TW202132269A (https=)
UA (1) UA129409C2 (https=)
WO (1) WO2021094563A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023218285A1 (en) * 2022-05-12 2023-11-16 Janssen Pharmaceuticals, Inc. Treatment or prevention of dengue viral infection
WO2025248536A1 (en) * 2024-05-29 2025-12-04 Zydus Lifesciences Limited Novel oxime derivatives to treat viral infections
WO2025253267A1 (en) 2024-06-06 2025-12-11 Janssen Pharmaceuticals, Inc. Combination of mosnodenvir and close analogs with nitd-688 for use in the treatment and prevention of dengue disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك

Also Published As

Publication number Publication date
KR20220101679A (ko) 2022-07-19
UA129409C2 (uk) 2025-04-16
CA3161338A1 (en) 2021-05-20
EP4058019A1 (en) 2022-09-21
JP2023502053A (ja) 2023-01-20
TW202132269A (zh) 2021-09-01
US20220409583A1 (en) 2022-12-29
CN114980884A (zh) 2022-08-30
PH12022551160A1 (en) 2023-09-25
WO2021094563A1 (en) 2021-05-20
MX2022005879A (es) 2022-06-14
IL292970A (en) 2022-07-01
BR112022009199A2 (pt) 2022-07-26

Similar Documents

Publication Publication Date Title
US20240269125A1 (en) Methods of treating coronavirus infections by co-administering an fkbp ligand and an antiviral agent
AU2020382911A1 (en) Treatment and prevention of Dengue disease
AU2014318488B2 (en) Deoxynojirimycin derivatives and methods of their using
CN109789147B (zh) 用于治疗非酒精性脂肪性肝病的药物组合物及方法
WO2003050129A1 (en) Use of phosphonate nucleotide analogue for treating hepatitis b virus infections
US20140275139A1 (en) Mdr method and products for treating hiv/aids
CA2945825C (en) Inhibition of flaviviruses or chikungunya viruses using retinoic acid analogues
Snell Examining unmet needs in infectious disease
Yeh et al. mk-8742, a Hcv Ns5a Inhibitor with a Broad Spectrum of Hcv Genotypic Activity, Demonstrates Potent Antiviral Activity in Genotype-1 and-3 Hcv-infected Patients: 479
EA049504B1 (ru) Лечение и профилактика лихорадки денге
US11975003B2 (en) Methods and compositions for treatment of Zika virus infection
CN102335171B (zh) 一类n-(2-噻唑)苯甲酰胺衍生物的应用
HK40074715A (en) Treatment and prevention of dengue disease
CN113440527B (zh) 萘酚喹或含萘酚喹的组合制剂在抗冠状病毒中的应用
EP3960173B1 (en) Enterovirus inhibitor
KR102405447B1 (ko) 5-(2-아마노에틸)-디벤조[cd,f]-인돌-4(5H)-온 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 포함하는 항 HIV-1용 약학적 조성물
US20170348330A1 (en) Antiviral compound and analogues thereof for treatment or prevention of flavivirus dengue/zika infections
CN106727574A (zh) 马尼地平在制备治疗黄病毒科病毒感染药物中的应用
Thys et al. R75761, a lead compound for the development of antiviral drugs in late stage poliomyelitis eradication strategies and beyond
JP2024533532A (ja) コロナウイルス感染症を処置するための新規の併用薬物、医薬組成物およびその使用